These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 30871669)

  • 21. Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic.
    Kunkel A; Crawford FW; Shepherd J; Cohen T
    AIDS; 2016 Nov; 30(17):2715-2723. PubMed ID: 27782966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preventing tuberculosis among HIV-infected pregnant women in Lesotho: the case for rolling out active case finding and isoniazid preventive therapy.
    Tiam A; Machekano R; Gounder CR; Maama-Maime LB; Ntene-Sealiete K; Sahu M; Isavwa A; Oyebanji O; Ahimbisibwe A; Mokone M; Barnes GL; Chaisson RE; Guay L; Kassaye S
    J Acquir Immune Defic Syndr; 2014 Sep; 67(1):e5-e11. PubMed ID: 25118796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Projected population-wide impact of antiretroviral therapy-linked isoniazid preventive therapy in a high-burden setting.
    Kendall EA; Azman AS; Maartens G; Boulle A; Wilkinson RJ; Dowdy DW; Rangaka MX
    AIDS; 2019 Mar; 33(3):525-536. PubMed ID: 30325773
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected adults in programme setting.
    Padmapriyadarsini C; Sekar L; Reddy D; Chitra A; Poornagangadevi N; Selvaraj M; Bhavani PK; Mothi SN; Nandagopal K; Vennila S; Tamizhselvan M; Maheshmanisha J; Agarwal U; Rewari BB; Swaminathan S
    Indian J Med Res; 2020 Dec; 152(6):648-655. PubMed ID: 34145105
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk-Benefit Analysis.
    Freiman JM; Jacobson KR; Muyindike WR; Horsburgh CR; Ellner JJ; Hahn JA; Linas BP
    J Acquir Immune Defic Syndr; 2018 Apr; 77(4):405-412. PubMed ID: 29239900
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determinants of isoniazid preventive therapy completion among people living with HIV attending care and treatment clinics from 2013 to 2017 in Dar es Salaam Region, Tanzania. A cross-sectional analytical study.
    Robert M; Todd J; Ngowi BJ; Msuya SE; Ramadhani A; Sambu V; Jerry I; Mujuni MR; Mahande MJ; Ngocho JS; Maokola W
    BMC Infect Dis; 2020 Apr; 20(1):276. PubMed ID: 32276618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implementation and Operational Research: Implementation of the WHO 2011 Recommendations for Isoniazid Preventive Therapy (IPT) in Children Living With HIV/AIDS: A Ugandan Experience.
    Costenaro P; Massavon W; Lundin R; Nabachwa SM; Fregonese F; Morelli E; Alowo A; Nannyonga Musoke M; Namisi CP; Kizito S; Bilardi D; Mazza A; Cotton MF; Giaquinto C; Penazzato M
    J Acquir Immune Defic Syndr; 2016 Jan; 71(1):e1-8. PubMed ID: 26761275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Completion of isoniazid preventive therapy and survival in HIV-infected, TST-positive adults in Tanzania.
    Kabali C; von Reyn CF; Brooks DR; Waddell R; Mtei L; Bakari M; Matee M; Pallangyo K; Arbeit RD; Horsburgh CR
    Int J Tuberc Lung Dis; 2011 Nov; 15(11):1515-21, i. PubMed ID: 22008766
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of adherence to isoniazid preventive therapy among HIV positive adults in Addis Ababa, Ethiopia.
    Mindachew M; Deribew A; Tessema F; Biadgilign S
    BMC Public Health; 2011 Dec; 11():916. PubMed ID: 22151609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Knowledge and adherence to isoniazid preventive therapy among people living with HIV in multilevel health facilities in South-East, Nigeria: baseline findings from a quasi-experimental study.
    Akamike IC; Okedo-Alex IN; Agu AP; Alo C; Ogbonnaya LU
    Pan Afr Med J; 2020; 36():261. PubMed ID: 33014257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modelling the performance of isoniazid preventive therapy for reducing tuberculosis in HIV endemic settings: the effects of network structure.
    Mills HL; Cohen T; Colijn C
    J R Soc Interface; 2011 Oct; 8(63):1510-20. PubMed ID: 21508012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving coverage and completion rate of isoniazid preventive therapy among eligible HIV patients using quality improvement approaches: a case study of State Hospital, Ijebu Ode, Ogun State, Nigeria.
    Ogunsola OO; Ajayi O; Ojo O; Adeyeye O; Akinro Y; Oke O; Adurogbola AA; Olajide O
    Pan Afr Med J; 2019; 34():193. PubMed ID: 32180867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isoniazid preventive therapy: Uptake, incidence of tuberculosis and survival among people living with HIV in Bulawayo, Zimbabwe.
    Nyathi S; Dlodlo RA; Satyanarayana S; Takarinda KC; Tweya H; Hove S; Matambo R; Mandewo W; Nyathi K; Sibanda E; Harries AD
    PLoS One; 2019; 14(10):e0223076. PubMed ID: 31581271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health system challenges: An obstacle to the success of isoniazid preventive therapy.
    Okoli EI; Roets L
    S Afr Med J; 2016 Nov; 106(11):1079-1081. PubMed ID: 27842624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survey of isoniazid preventive therapy in South Africa, 2011.
    Chehab JC; Vilakazi-Nhlapo K; Vranken P; Peters A; Klausner JD
    Int J Tuberc Lung Dis; 2012 Jul; 16(7):903-7. PubMed ID: 22583688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Barriers in the implementation of isoniazid preventive therapy for people living with HIV in Northern Ethiopia: a mixed quantitative and qualitative study.
    Teklay G; Teklu T; Legesse B; Tedla K; Klinkenberg E
    BMC Public Health; 2016 Aug; 16(1):840. PubMed ID: 27543096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High completion rates of isoniazid preventive therapy among persons living with HIV in Swaziland.
    Adams LV; Mahlalela N; Talbot EA; Pasipamire M; Ginindza S; Calnan M; Haumba S
    Int J Tuberc Lung Dis; 2017 Oct; 21(10):1127-1132. PubMed ID: 28911356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Programmatic Evaluation of an Algorithm for Intensified Tuberculosis Case Finding and Isoniazid Preventive Therapy for People Living With HIV in Thailand and Vietnam.
    Cowger TL; Thai LH; Duong BD; Danyuttapolchai J; Kittimunkong S; Nhung NV; Nhan DT; Monkongdee P; Thoa CK; Khanh VT; Nateniyom S; Yen NTB; Ngoc DV; Thinh T; Whitehead S; Pevzner ES
    J Acquir Immune Defic Syndr; 2017 Dec; 76(5):512-521. PubMed ID: 29023251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Screening for active tuberculosis before isoniazid preventive therapy among HIV-infected West African adults.
    Moh R; Badjé A; N'takpé JB; Kouamé GM; Gabillard D; Ouassa T; Ouattara E; Le Carrou J; Bohoussou F; Messou E; Eholié S; Anglaret X; Danel C
    Int J Tuberc Lung Dis; 2017 Dec; 21(12):1237-1244. PubMed ID: 29297443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence and associated factors of tuberculosis among isoniazid users and non-users of HIV patients in Dessie, Ethiopia.
    Mebratu W; Wedajo S; Mohammed S; Endawkie A; Damtew Y
    Sci Rep; 2022 Aug; 12(1):13500. PubMed ID: 35931781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.